405 related articles for article (PubMed ID: 29656235)
21. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
22. Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
Seth A; Heo MB; Lim YT
Biomaterials; 2014 Sep; 35(27):7992-8001. PubMed ID: 24954733
[TBL] [Abstract][Full Text] [Related]
23. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice.
Wen L; Xin B; Wu P; Lin CH; Peng C; Wang G; Lee J; Lu LF; Feng GS
Hepatology; 2019 Jun; 69(6):2518-2532. PubMed ID: 30693544
[TBL] [Abstract][Full Text] [Related]
24. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
25. Synthetic Polymeric Mixed Micelles Targeting Lymph Nodes Trigger Enhanced Cellular and Humoral Immune Responses.
Li C; Zhang X; Chen Q; Zhang J; Li W; Hu H; Zhao X; Qiao M; Chen D
ACS Appl Mater Interfaces; 2018 Jan; 10(3):2874-2889. PubMed ID: 29285934
[TBL] [Abstract][Full Text] [Related]
26. Multi-functional nanocomplex codelivery of Trp2 and R837 to activate melanoma-specific immunity.
Ji Z; Tan Z; Li M; Tao J; Guan E; Du J; Hu Y
Int J Pharm; 2020 May; 582():119310. PubMed ID: 32276088
[TBL] [Abstract][Full Text] [Related]
27. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
28. An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system.
Cobaleda-Siles M; Henriksen-Lacey M; Ruiz de Angulo A; Bernecker A; Gómez Vallejo V; Szczupak B; Llop J; Pastor G; Plaza-Garcia S; Jauregui-Osoro M; Meszaros LK; Mareque-Rivas JC
Small; 2014 Dec; 10(24):5054-67. PubMed ID: 25123704
[TBL] [Abstract][Full Text] [Related]
29. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
30. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
31. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
32. Photothermal-Activatable Fe
Ge R; Liu C; Zhang X; Wang W; Li B; Liu J; Liu Y; Sun H; Zhang D; Hou Y; Zhang H; Yang B
ACS Appl Mater Interfaces; 2018 Jun; 10(24):20342-20355. PubMed ID: 29878757
[TBL] [Abstract][Full Text] [Related]
33. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
[TBL] [Abstract][Full Text] [Related]
34. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
35. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Caisová V; Uher O; Nedbalová P; Jochmanová I; Kvardová K; Masáková K; Krejčová G; Paďouková L; Chmelař J; Kopecký J; Ženka J
Int Immunopharmacol; 2018 Jun; 59():86-96. PubMed ID: 29635103
[TBL] [Abstract][Full Text] [Related]
36. Intravenous liposomal vaccine enhances CTL generation, but not until antigen presentation.
Nakamura T; Haloho SEE; Harashima H
J Control Release; 2022 Mar; 343():1-12. PubMed ID: 35065157
[TBL] [Abstract][Full Text] [Related]
37. Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
Caisová V; Vieru A; Kumžáková Z; Glaserová S; Husníková H; Vácová N; Krejčová G; Paďouková L; Jochmanová I; Wolf KI; Chmelař J; Kopecký J; Ženka J
BMC Cancer; 2016 Dec; 16(1):940. PubMed ID: 27927165
[TBL] [Abstract][Full Text] [Related]
38. Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (β-amino ester) nano-vaccines for melanoma.
Zou C; Jiang G; Gao X; Zhang W; Deng H; Zhang C; Ding J; Wei R; Wang X; Xi L; Tan S
Nanomedicine; 2019 Nov; 22():102092. PubMed ID: 31593795
[TBL] [Abstract][Full Text] [Related]
39. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
40. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
